nodes	percent_of_prediction	percent_of_DWPC	metapath
Entacapone—COMT—Estrogen metabolism—UGT2B7—urinary bladder cancer	0.0273	0.0754	CbGpPWpGaD
Entacapone—UGT1A9—Arylamine metabolism—NAT2—urinary bladder cancer	0.0236	0.0651	CbGpPWpGaD
Entacapone—UGT1A9—Estrogen metabolism—UGT2B7—urinary bladder cancer	0.0163	0.0451	CbGpPWpGaD
Entacapone—UGT1A9—Glucuronidation—UGT2B7—urinary bladder cancer	0.015	0.0415	CbGpPWpGaD
Entacapone—COMT—Dopamine metabolism—NQO1—urinary bladder cancer	0.0137	0.0377	CbGpPWpGaD
Entacapone—UGT1A9—Glucuronidation—UGT2B7—urinary bladder cancer	0.0122	0.0336	CbGpPWpGaD
Entacapone—COMT—Estrogen metabolism—NQO1—urinary bladder cancer	0.0105	0.0291	CbGpPWpGaD
Entacapone—COMT—Phase II conjugation—GSTZ1—urinary bladder cancer	0.00884	0.0244	CbGpPWpGaD
Entacapone—COMT—Phase II conjugation—NAT1—urinary bladder cancer	0.00838	0.0231	CbGpPWpGaD
Entacapone—COMT—Phase II conjugation—GSTO2—urinary bladder cancer	0.00838	0.0231	CbGpPWpGaD
Entacapone—COMT—Estrogen metabolism—GSTM1—urinary bladder cancer	0.00807	0.0223	CbGpPWpGaD
Entacapone—UGT1A9—renal system—urinary bladder cancer	0.00781	0.191	CbGeAlD
Entacapone—COMT—Phase II conjugation—UGT2B7—urinary bladder cancer	0.00767	0.0212	CbGpPWpGaD
Entacapone—UGT1A9—Estrogen metabolism—NQO1—urinary bladder cancer	0.00631	0.0174	CbGpPWpGaD
Entacapone—COMT—prostate gland—urinary bladder cancer	0.00628	0.154	CbGeAlD
Entacapone—COMT—seminal vesicle—urinary bladder cancer	0.00531	0.13	CbGeAlD
Entacapone—UGT1A9—Phase II conjugation—GSTZ1—urinary bladder cancer	0.0053	0.0146	CbGpPWpGaD
Entacapone—COMT—Biological oxidations—GSTZ1—urinary bladder cancer	0.00517	0.0143	CbGpPWpGaD
Entacapone—COMT—Metapathway biotransformation—GSTZ1—urinary bladder cancer	0.0051	0.0141	CbGpPWpGaD
Entacapone—UGT1A9—Phase II conjugation—GSTO2—urinary bladder cancer	0.00502	0.0139	CbGpPWpGaD
Entacapone—UGT1A9—Phase II conjugation—NAT1—urinary bladder cancer	0.00502	0.0139	CbGpPWpGaD
Entacapone—COMT—Biological oxidations—GSTO2—urinary bladder cancer	0.0049	0.0135	CbGpPWpGaD
Entacapone—COMT—Biological oxidations—NAT1—urinary bladder cancer	0.0049	0.0135	CbGpPWpGaD
Entacapone—UGT1A9—Estrogen metabolism—GSTM1—urinary bladder cancer	0.00484	0.0134	CbGpPWpGaD
Entacapone—COMT—Metapathway biotransformation—GSTO2—urinary bladder cancer	0.00484	0.0134	CbGpPWpGaD
Entacapone—UGT1A9—Phase II conjugation—UGT2B7—urinary bladder cancer	0.00459	0.0127	CbGpPWpGaD
Entacapone—COMT—Phase II conjugation—NAT2—urinary bladder cancer	0.00459	0.0127	CbGpPWpGaD
Entacapone—UGT1A9—Constitutive Androstane Receptor Pathway—SMC1A—urinary bladder cancer	0.00454	0.0125	CbGpPWpGaD
Entacapone—COMT—Biological oxidations—UGT2B7—urinary bladder cancer	0.00448	0.0124	CbGpPWpGaD
Entacapone—COMT—smooth muscle tissue—urinary bladder cancer	0.00444	0.109	CbGeAlD
Entacapone—COMT—Metapathway biotransformation—UGT2B7—urinary bladder cancer	0.00442	0.0122	CbGpPWpGaD
Entacapone—COMT—renal system—urinary bladder cancer	0.00428	0.105	CbGeAlD
Entacapone—COMT—urethra—urinary bladder cancer	0.0042	0.103	CbGeAlD
Entacapone—COMT—Biological oxidations—CYP4B1—urinary bladder cancer	0.00404	0.0112	CbGpPWpGaD
Entacapone—COMT—Metapathway biotransformation—CYP4B1—urinary bladder cancer	0.00398	0.011	CbGpPWpGaD
Entacapone—COMT—Phase II conjugation—HPGDS—urinary bladder cancer	0.00367	0.0101	CbGpPWpGaD
Entacapone—COMT—Phase II conjugation—GSTT1—urinary bladder cancer	0.00356	0.00983	CbGpPWpGaD
Entacapone—COMT—female reproductive system—urinary bladder cancer	0.00343	0.0839	CbGeAlD
Entacapone—UGT1A9—Biological oxidations—GSTZ1—urinary bladder cancer	0.0031	0.00856	CbGpPWpGaD
Entacapone—COMT—vagina—urinary bladder cancer	0.0031	0.0759	CbGeAlD
Entacapone—UGT1A9—NRF2 pathway—UGT2B7—urinary bladder cancer	0.00306	0.00846	CbGpPWpGaD
Entacapone—UGT1A9—Metapathway biotransformation—GSTZ1—urinary bladder cancer	0.00306	0.00844	CbGpPWpGaD
Entacapone—UGT1A9—Aryl Hydrocarbon Receptor Pathway—NQO1—urinary bladder cancer	0.00298	0.00823	CbGpPWpGaD
Entacapone—UGT1A9—Biological oxidations—GSTO2—urinary bladder cancer	0.00294	0.00811	CbGpPWpGaD
Entacapone—UGT1A9—Biological oxidations—NAT1—urinary bladder cancer	0.00294	0.00811	CbGpPWpGaD
Entacapone—UGT1A9—Metapathway biotransformation—GSTO2—urinary bladder cancer	0.0029	0.008	CbGpPWpGaD
Entacapone—UGT1A9—PPAR Alpha Pathway—CDK4—urinary bladder cancer	0.00284	0.00785	CbGpPWpGaD
Entacapone—UGT1A9—Phase II conjugation—NAT2—urinary bladder cancer	0.00275	0.0076	CbGpPWpGaD
Entacapone—COMT—Biological oxidations—NAT2—urinary bladder cancer	0.00269	0.00742	CbGpPWpGaD
Entacapone—UGT1A9—Biological oxidations—UGT2B7—urinary bladder cancer	0.00269	0.00742	CbGpPWpGaD
Entacapone—COMT—Metapathway biotransformation—NAT2—urinary bladder cancer	0.00265	0.00732	CbGpPWpGaD
Entacapone—UGT1A9—Metapathway biotransformation—UGT2B7—urinary bladder cancer	0.00265	0.00732	CbGpPWpGaD
Entacapone—COMT—Phase II conjugation—GSTP1—urinary bladder cancer	0.00247	0.00682	CbGpPWpGaD
Entacapone—UGT1A9—Biological oxidations—CYP4B1—urinary bladder cancer	0.00242	0.00668	CbGpPWpGaD
Entacapone—UGT1A9—Metapathway biotransformation—CYP4B1—urinary bladder cancer	0.00239	0.00659	CbGpPWpGaD
Entacapone—COMT—Phase II conjugation—GSTM1—urinary bladder cancer	0.00227	0.00626	CbGpPWpGaD
Entacapone—UGT1A9—Phase II conjugation—HPGDS—urinary bladder cancer	0.0022	0.00607	CbGpPWpGaD
Entacapone—COMT—Biological oxidations—HPGDS—urinary bladder cancer	0.00215	0.00593	CbGpPWpGaD
Entacapone—UGT1A9—Phase II conjugation—GSTT1—urinary bladder cancer	0.00213	0.00589	CbGpPWpGaD
Entacapone—COMT—Biological oxidations—GSTT1—urinary bladder cancer	0.00208	0.00575	CbGpPWpGaD
Entacapone—COMT—lymph node—urinary bladder cancer	0.002	0.0491	CbGeAlD
Entacapone—UGT1A9—PPAR Alpha Pathway—CCND1—urinary bladder cancer	0.00184	0.00507	CbGpPWpGaD
Entacapone—UGT1A9—Biological oxidations—NAT2—urinary bladder cancer	0.00161	0.00444	CbGpPWpGaD
Entacapone—UGT1A9—Metapathway biotransformation—NAT2—urinary bladder cancer	0.00159	0.00438	CbGpPWpGaD
Entacapone—UGT1A9—Phase II conjugation—GSTP1—urinary bladder cancer	0.00148	0.00408	CbGpPWpGaD
Entacapone—UGT1A9—PPAR Alpha Pathway—MYC—urinary bladder cancer	0.00147	0.00407	CbGpPWpGaD
Entacapone—COMT—Biological oxidations—GSTP1—urinary bladder cancer	0.00144	0.00399	CbGpPWpGaD
Entacapone—COMT—Metapathway biotransformation—GSTP1—urinary bladder cancer	0.00142	0.00393	CbGpPWpGaD
Entacapone—UGT1A9—Phase II conjugation—GSTM1—urinary bladder cancer	0.00136	0.00375	CbGpPWpGaD
Entacapone—COMT—Biological oxidations—GSTM1—urinary bladder cancer	0.00133	0.00366	CbGpPWpGaD
Entacapone—COMT—Metapathway biotransformation—GSTM1—urinary bladder cancer	0.00131	0.00361	CbGpPWpGaD
Entacapone—UGT1A9—Biological oxidations—HPGDS—urinary bladder cancer	0.00129	0.00355	CbGpPWpGaD
Entacapone—UGT1A9—Biological oxidations—GSTT1—urinary bladder cancer	0.00125	0.00345	CbGpPWpGaD
Entacapone—UGT1A9—Aryl Hydrocarbon Receptor Pathway—IL2—urinary bladder cancer	0.00119	0.00329	CbGpPWpGaD
Entacapone—UGT1A9—NRF2 pathway—NQO1—urinary bladder cancer	0.00118	0.00327	CbGpPWpGaD
Entacapone—UGT1A9—PPARA activates gene expression—NCOR1—urinary bladder cancer	0.00114	0.00314	CbGpPWpGaD
Entacapone—UGT1A9—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—NCOR1—urinary bladder cancer	0.00111	0.00307	CbGpPWpGaD
Entacapone—UGT1A9—Aryl Hydrocarbon Receptor Pathway—EP300—urinary bladder cancer	0.00107	0.00296	CbGpPWpGaD
Entacapone—UGT1A9—Aryl Hydrocarbon Receptor Pathway—SRC—urinary bladder cancer	0.00104	0.00287	CbGpPWpGaD
Entacapone—UGT1A9—NRF2 pathway—GSTP1—urinary bladder cancer	0.000986	0.00272	CbGpPWpGaD
Entacapone—UGT1A9—Metabolism of lipids and lipoproteins—CYP4B1—urinary bladder cancer	0.000929	0.00257	CbGpPWpGaD
Entacapone—UGT1A9—Aryl Hydrocarbon Receptor Pathway—EGFR—urinary bladder cancer	0.000912	0.00252	CbGpPWpGaD
Entacapone—UGT1A9—NRF2 pathway—GSTM1—urinary bladder cancer	0.000906	0.0025	CbGpPWpGaD
Entacapone—COMT—Metabolism—GSTZ1—urinary bladder cancer	0.000884	0.00244	CbGpPWpGaD
Entacapone—UGT1A9—Aryl Hydrocarbon Receptor Pathway—TNF—urinary bladder cancer	0.000869	0.0024	CbGpPWpGaD
Entacapone—UGT1A9—Biological oxidations—GSTP1—urinary bladder cancer	0.000865	0.00239	CbGpPWpGaD
Entacapone—UGT1A9—Metapathway biotransformation—GSTP1—urinary bladder cancer	0.000853	0.00236	CbGpPWpGaD
Entacapone—COMT—Metabolism—GSTO2—urinary bladder cancer	0.000838	0.00232	CbGpPWpGaD
Entacapone—COMT—Metabolism—NAT1—urinary bladder cancer	0.000838	0.00232	CbGpPWpGaD
Entacapone—UGT1A9—PPARA activates gene expression—PPARG—urinary bladder cancer	0.000815	0.00225	CbGpPWpGaD
Entacapone—UGT1A9—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—PPARG—urinary bladder cancer	0.000797	0.0022	CbGpPWpGaD
Entacapone—UGT1A9—Biological oxidations—GSTM1—urinary bladder cancer	0.000795	0.0022	CbGpPWpGaD
Entacapone—UGT1A9—Metapathway biotransformation—GSTM1—urinary bladder cancer	0.000784	0.00217	CbGpPWpGaD
Entacapone—UGT1A9—PPARA activates gene expression—CREBBP—urinary bladder cancer	0.000782	0.00216	CbGpPWpGaD
Entacapone—COMT—Metabolism—UGT2B7—urinary bladder cancer	0.000767	0.00212	CbGpPWpGaD
Entacapone—UGT1A9—Fatty acid, triacylglycerol, and ketone body metabolism—NCOR1—urinary bladder cancer	0.000766	0.00212	CbGpPWpGaD
Entacapone—UGT1A9—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—CREBBP—urinary bladder cancer	0.000766	0.00211	CbGpPWpGaD
Entacapone—COMT—Metabolism—CYP4B1—urinary bladder cancer	0.00069	0.00191	CbGpPWpGaD
Entacapone—COMT—Metabolism—SLC19A1—urinary bladder cancer	0.000652	0.0018	CbGpPWpGaD
Entacapone—COMT—Metabolism—PRSS3—urinary bladder cancer	0.000635	0.00175	CbGpPWpGaD
Entacapone—UGT1A9—Fatty acid, triacylglycerol, and ketone body metabolism—PPARG—urinary bladder cancer	0.000549	0.00152	CbGpPWpGaD
Entacapone—UGT1A9—PPARA activates gene expression—EP300—urinary bladder cancer	0.000533	0.00147	CbGpPWpGaD
Entacapone—UGT1A9—Metabolism—GSTZ1—urinary bladder cancer	0.00053	0.00146	CbGpPWpGaD
Entacapone—UGT1A9—Fatty acid, triacylglycerol, and ketone body metabolism—CREBBP—urinary bladder cancer	0.000528	0.00146	CbGpPWpGaD
Entacapone—UGT1A9—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—EP300—urinary bladder cancer	0.000522	0.00144	CbGpPWpGaD
Entacapone—COMT—Metabolism—TYMP—urinary bladder cancer	0.000508	0.0014	CbGpPWpGaD
Entacapone—UGT1A9—Metabolism—GSTO2—urinary bladder cancer	0.000502	0.00139	CbGpPWpGaD
Entacapone—UGT1A9—Metabolism—NAT1—urinary bladder cancer	0.000502	0.00139	CbGpPWpGaD
Entacapone—UGT1A9—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	0.000494	0.00136	CbGpPWpGaD
Entacapone—UGT1A9—Metabolism—UGT2B7—urinary bladder cancer	0.000459	0.00127	CbGpPWpGaD
Entacapone—COMT—Metabolism—NAT2—urinary bladder cancer	0.000459	0.00127	CbGpPWpGaD
Entacapone—Feeling abnormal—Etoposide—urinary bladder cancer	0.000427	0.000715	CcSEcCtD
Entacapone—Hyperglycaemia—Doxorubicin—urinary bladder cancer	0.000426	0.000714	CcSEcCtD
Entacapone—Agranulocytosis—Epirubicin—urinary bladder cancer	0.000425	0.000711	CcSEcCtD
Entacapone—Pneumonia—Doxorubicin—urinary bladder cancer	0.000424	0.000709	CcSEcCtD
Entacapone—Gastrointestinal pain—Etoposide—urinary bladder cancer	0.000423	0.000709	CcSEcCtD
Entacapone—Pruritus—Fluorouracil—urinary bladder cancer	0.000422	0.000707	CcSEcCtD
Entacapone—Visual impairment—Methotrexate—urinary bladder cancer	0.000421	0.000705	CcSEcCtD
Entacapone—Hypersensitivity—Cisplatin—urinary bladder cancer	0.000416	0.000697	CcSEcCtD
Entacapone—Bradycardia—Epirubicin—urinary bladder cancer	0.000416	0.000697	CcSEcCtD
Entacapone—Diarrhoea—Gemcitabine—urinary bladder cancer	0.000415	0.000695	CcSEcCtD
Entacapone—UGT1A9—Metabolism—CYP4B1—urinary bladder cancer	0.000414	0.00114	CbGpPWpGaD
Entacapone—Erythema multiforme—Methotrexate—urinary bladder cancer	0.000413	0.000691	CcSEcCtD
Entacapone—Neuropathy peripheral—Doxorubicin—urinary bladder cancer	0.000413	0.000691	CcSEcCtD
Entacapone—Urticaria—Etoposide—urinary bladder cancer	0.000411	0.000689	CcSEcCtD
Entacapone—Haemoglobin—Epirubicin—urinary bladder cancer	0.000411	0.000688	CcSEcCtD
Entacapone—Abdominal pain—Etoposide—urinary bladder cancer	0.000409	0.000686	CcSEcCtD
Entacapone—Body temperature increased—Etoposide—urinary bladder cancer	0.000409	0.000686	CcSEcCtD
Entacapone—Conjunctivitis—Doxorubicin—urinary bladder cancer	0.000409	0.000686	CcSEcCtD
Entacapone—Urinary tract infection—Doxorubicin—urinary bladder cancer	0.000409	0.000686	CcSEcCtD
Entacapone—Haemorrhage—Epirubicin—urinary bladder cancer	0.000409	0.000684	CcSEcCtD
Entacapone—Hepatitis—Epirubicin—urinary bladder cancer	0.000409	0.000684	CcSEcCtD
Entacapone—Eye disorder—Methotrexate—urinary bladder cancer	0.000408	0.000683	CcSEcCtD
Entacapone—Diarrhoea—Fluorouracil—urinary bladder cancer	0.000408	0.000683	CcSEcCtD
Entacapone—Hypoaesthesia—Epirubicin—urinary bladder cancer	0.000407	0.000681	CcSEcCtD
Entacapone—Asthenia—Cisplatin—urinary bladder cancer	0.000406	0.000679	CcSEcCtD
Entacapone—Pharyngitis—Epirubicin—urinary bladder cancer	0.000406	0.000679	CcSEcCtD
Entacapone—Cardiac disorder—Methotrexate—urinary bladder cancer	0.000405	0.000679	CcSEcCtD
Entacapone—Sweating—Doxorubicin—urinary bladder cancer	0.000404	0.000676	CcSEcCtD
Entacapone—Urinary tract disorder—Epirubicin—urinary bladder cancer	0.000404	0.000676	CcSEcCtD
Entacapone—Haematuria—Doxorubicin—urinary bladder cancer	0.000402	0.000672	CcSEcCtD
Entacapone—Urethral disorder—Epirubicin—urinary bladder cancer	0.000401	0.000671	CcSEcCtD
Entacapone—Hepatobiliary disease—Doxorubicin—urinary bladder cancer	0.000398	0.000667	CcSEcCtD
Entacapone—Epistaxis—Doxorubicin—urinary bladder cancer	0.000397	0.000665	CcSEcCtD
Entacapone—COMT—Metabolism—RRM2—urinary bladder cancer	0.000397	0.0011	CbGpPWpGaD
Entacapone—Sinusitis—Doxorubicin—urinary bladder cancer	0.000395	0.000662	CcSEcCtD
Entacapone—Dizziness—Fluorouracil—urinary bladder cancer	0.000394	0.00066	CcSEcCtD
Entacapone—Visual impairment—Epirubicin—urinary bladder cancer	0.000394	0.000659	CcSEcCtD
Entacapone—Agranulocytosis—Doxorubicin—urinary bladder cancer	0.000393	0.000658	CcSEcCtD
Entacapone—UGT1A9—Metabolism—SLC19A1—urinary bladder cancer	0.000391	0.00108	CbGpPWpGaD
Entacapone—Diarrhoea—Cisplatin—urinary bladder cancer	0.000387	0.000648	CcSEcCtD
Entacapone—Erythema multiforme—Epirubicin—urinary bladder cancer	0.000386	0.000647	CcSEcCtD
Entacapone—Alopecia—Methotrexate—urinary bladder cancer	0.000386	0.000646	CcSEcCtD
Entacapone—Vomiting—Gemcitabine—urinary bladder cancer	0.000386	0.000646	CcSEcCtD
Entacapone—Bradycardia—Doxorubicin—urinary bladder cancer	0.000385	0.000645	CcSEcCtD
Entacapone—Mental disorder—Methotrexate—urinary bladder cancer	0.000383	0.000641	CcSEcCtD
Entacapone—Rash—Gemcitabine—urinary bladder cancer	0.000382	0.00064	CcSEcCtD
Entacapone—Dermatitis—Gemcitabine—urinary bladder cancer	0.000382	0.00064	CcSEcCtD
Entacapone—Eye disorder—Epirubicin—urinary bladder cancer	0.000382	0.00064	CcSEcCtD
Entacapone—Hypersensitivity—Etoposide—urinary bladder cancer	0.000382	0.000639	CcSEcCtD
Entacapone—UGT1A9—Metabolism—PRSS3—urinary bladder cancer	0.000381	0.00105	CbGpPWpGaD
Entacapone—Malnutrition—Methotrexate—urinary bladder cancer	0.00038	0.000637	CcSEcCtD
Entacapone—Haemoglobin—Doxorubicin—urinary bladder cancer	0.00038	0.000636	CcSEcCtD
Entacapone—Headache—Gemcitabine—urinary bladder cancer	0.00038	0.000636	CcSEcCtD
Entacapone—Cardiac disorder—Epirubicin—urinary bladder cancer	0.000379	0.000635	CcSEcCtD
Entacapone—Flushing—Epirubicin—urinary bladder cancer	0.000379	0.000635	CcSEcCtD
Entacapone—Vomiting—Fluorouracil—urinary bladder cancer	0.000379	0.000635	CcSEcCtD
Entacapone—Hepatitis—Doxorubicin—urinary bladder cancer	0.000378	0.000633	CcSEcCtD
Entacapone—Haemorrhage—Doxorubicin—urinary bladder cancer	0.000378	0.000633	CcSEcCtD
Entacapone—COMT—Transmission across Chemical Synapses—HRAS—urinary bladder cancer	0.000377	0.00104	CbGpPWpGaD
Entacapone—Hypoaesthesia—Doxorubicin—urinary bladder cancer	0.000376	0.00063	CcSEcCtD
Entacapone—Rash—Fluorouracil—urinary bladder cancer	0.000376	0.00063	CcSEcCtD
Entacapone—Dermatitis—Fluorouracil—urinary bladder cancer	0.000376	0.000629	CcSEcCtD
Entacapone—Pharyngitis—Doxorubicin—urinary bladder cancer	0.000375	0.000628	CcSEcCtD
Entacapone—Headache—Fluorouracil—urinary bladder cancer	0.000374	0.000626	CcSEcCtD
Entacapone—Urinary tract disorder—Doxorubicin—urinary bladder cancer	0.000373	0.000625	CcSEcCtD
Entacapone—Dysgeusia—Methotrexate—urinary bladder cancer	0.000372	0.000623	CcSEcCtD
Entacapone—Asthenia—Etoposide—urinary bladder cancer	0.000372	0.000622	CcSEcCtD
Entacapone—Urethral disorder—Doxorubicin—urinary bladder cancer	0.000371	0.000621	CcSEcCtD
Entacapone—Back pain—Methotrexate—urinary bladder cancer	0.000368	0.000616	CcSEcCtD
Entacapone—COMT—Metabolism—HPGDS—urinary bladder cancer	0.000367	0.00101	CbGpPWpGaD
Entacapone—COMT—Metabolism—ENO2—urinary bladder cancer	0.000367	0.00101	CbGpPWpGaD
Entacapone—Pruritus—Etoposide—urinary bladder cancer	0.000366	0.000614	CcSEcCtD
Entacapone—Visual impairment—Doxorubicin—urinary bladder cancer	0.000364	0.00061	CcSEcCtD
Entacapone—Alopecia—Epirubicin—urinary bladder cancer	0.000361	0.000605	CcSEcCtD
Entacapone—Nausea—Gemcitabine—urinary bladder cancer	0.00036	0.000603	CcSEcCtD
Entacapone—Vomiting—Cisplatin—urinary bladder cancer	0.000359	0.000602	CcSEcCtD
Entacapone—UGT1A9—Fatty acid, triacylglycerol, and ketone body metabolism—EP300—urinary bladder cancer	0.000359	0.000993	CbGpPWpGaD
Entacapone—Vision blurred—Methotrexate—urinary bladder cancer	0.000358	0.0006	CcSEcCtD
Entacapone—Mental disorder—Epirubicin—urinary bladder cancer	0.000358	0.0006	CcSEcCtD
Entacapone—Erythema multiforme—Doxorubicin—urinary bladder cancer	0.000357	0.000599	CcSEcCtD
Entacapone—Rash—Cisplatin—urinary bladder cancer	0.000356	0.000597	CcSEcCtD
Entacapone—COMT—Metabolism—GSTT1—urinary bladder cancer	0.000356	0.000984	CbGpPWpGaD
Entacapone—Dermatitis—Cisplatin—urinary bladder cancer	0.000356	0.000596	CcSEcCtD
Entacapone—Malnutrition—Epirubicin—urinary bladder cancer	0.000356	0.000596	CcSEcCtD
Entacapone—Diarrhoea—Etoposide—urinary bladder cancer	0.000354	0.000593	CcSEcCtD
Entacapone—Nausea—Fluorouracil—urinary bladder cancer	0.000354	0.000593	CcSEcCtD
Entacapone—Eye disorder—Doxorubicin—urinary bladder cancer	0.000353	0.000592	CcSEcCtD
Entacapone—Ill-defined disorder—Methotrexate—urinary bladder cancer	0.000353	0.000591	CcSEcCtD
Entacapone—Cardiac disorder—Doxorubicin—urinary bladder cancer	0.000351	0.000588	CcSEcCtD
Entacapone—Flushing—Doxorubicin—urinary bladder cancer	0.000351	0.000588	CcSEcCtD
Entacapone—Flatulence—Epirubicin—urinary bladder cancer	0.00035	0.000587	CcSEcCtD
Entacapone—Tension—Epirubicin—urinary bladder cancer	0.000349	0.000585	CcSEcCtD
Entacapone—Dysgeusia—Epirubicin—urinary bladder cancer	0.000348	0.000583	CcSEcCtD
Entacapone—Nervousness—Epirubicin—urinary bladder cancer	0.000345	0.000579	CcSEcCtD
Entacapone—Back pain—Epirubicin—urinary bladder cancer	0.000344	0.000576	CcSEcCtD
Entacapone—Malaise—Methotrexate—urinary bladder cancer	0.000343	0.000574	CcSEcCtD
Entacapone—Dizziness—Etoposide—urinary bladder cancer	0.000342	0.000574	CcSEcCtD
Entacapone—Muscle spasms—Epirubicin—urinary bladder cancer	0.000342	0.000573	CcSEcCtD
Entacapone—Vertigo—Methotrexate—urinary bladder cancer	0.000341	0.000572	CcSEcCtD
Entacapone—Leukopenia—Methotrexate—urinary bladder cancer	0.00034	0.00057	CcSEcCtD
Entacapone—Nausea—Cisplatin—urinary bladder cancer	0.000336	0.000562	CcSEcCtD
Entacapone—Vision blurred—Epirubicin—urinary bladder cancer	0.000335	0.000561	CcSEcCtD
Entacapone—Alopecia—Doxorubicin—urinary bladder cancer	0.000334	0.00056	CcSEcCtD
Entacapone—Cough—Methotrexate—urinary bladder cancer	0.000332	0.000555	CcSEcCtD
Entacapone—Mental disorder—Doxorubicin—urinary bladder cancer	0.000331	0.000555	CcSEcCtD
Entacapone—Ill-defined disorder—Epirubicin—urinary bladder cancer	0.00033	0.000553	CcSEcCtD
Entacapone—Convulsion—Methotrexate—urinary bladder cancer	0.000329	0.000552	CcSEcCtD
Entacapone—Vomiting—Etoposide—urinary bladder cancer	0.000329	0.000551	CcSEcCtD
Entacapone—Malnutrition—Doxorubicin—urinary bladder cancer	0.000329	0.000551	CcSEcCtD
Entacapone—Agitation—Epirubicin—urinary bladder cancer	0.000327	0.000547	CcSEcCtD
Entacapone—Rash—Etoposide—urinary bladder cancer	0.000327	0.000547	CcSEcCtD
Entacapone—Dermatitis—Etoposide—urinary bladder cancer	0.000326	0.000546	CcSEcCtD
Entacapone—Headache—Etoposide—urinary bladder cancer	0.000324	0.000543	CcSEcCtD
Entacapone—Flatulence—Doxorubicin—urinary bladder cancer	0.000324	0.000543	CcSEcCtD
Entacapone—Chest pain—Methotrexate—urinary bladder cancer	0.000324	0.000542	CcSEcCtD
Entacapone—Myalgia—Methotrexate—urinary bladder cancer	0.000324	0.000542	CcSEcCtD
Entacapone—Tension—Doxorubicin—urinary bladder cancer	0.000323	0.000541	CcSEcCtD
Entacapone—Dysgeusia—Doxorubicin—urinary bladder cancer	0.000322	0.00054	CcSEcCtD
Entacapone—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	0.000321	0.000538	CcSEcCtD
Entacapone—Malaise—Epirubicin—urinary bladder cancer	0.000321	0.000537	CcSEcCtD
Entacapone—Discomfort—Methotrexate—urinary bladder cancer	0.00032	0.000535	CcSEcCtD
Entacapone—Nervousness—Doxorubicin—urinary bladder cancer	0.00032	0.000535	CcSEcCtD
Entacapone—Vertigo—Epirubicin—urinary bladder cancer	0.00032	0.000535	CcSEcCtD
Entacapone—Syncope—Epirubicin—urinary bladder cancer	0.000319	0.000534	CcSEcCtD
Entacapone—Leukopenia—Epirubicin—urinary bladder cancer	0.000318	0.000533	CcSEcCtD
Entacapone—Back pain—Doxorubicin—urinary bladder cancer	0.000318	0.000533	CcSEcCtD
Entacapone—Muscle spasms—Doxorubicin—urinary bladder cancer	0.000316	0.00053	CcSEcCtD
Entacapone—Palpitations—Epirubicin—urinary bladder cancer	0.000314	0.000526	CcSEcCtD
Entacapone—Confusional state—Methotrexate—urinary bladder cancer	0.000313	0.000524	CcSEcCtD
Entacapone—Loss of consciousness—Epirubicin—urinary bladder cancer	0.000313	0.000524	CcSEcCtD
Entacapone—Cough—Epirubicin—urinary bladder cancer	0.00031	0.00052	CcSEcCtD
Entacapone—Vision blurred—Doxorubicin—urinary bladder cancer	0.00031	0.000519	CcSEcCtD
Entacapone—Convulsion—Epirubicin—urinary bladder cancer	0.000308	0.000516	CcSEcCtD
Entacapone—Nausea—Etoposide—urinary bladder cancer	0.000308	0.000515	CcSEcCtD
Entacapone—Hypertension—Epirubicin—urinary bladder cancer	0.000307	0.000514	CcSEcCtD
Entacapone—Ill-defined disorder—Doxorubicin—urinary bladder cancer	0.000305	0.000511	CcSEcCtD
Entacapone—UGT1A9—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	0.000305	0.000843	CbGpPWpGaD
Entacapone—UGT1A9—Metabolism—TYMP—urinary bladder cancer	0.000304	0.00084	CbGpPWpGaD
Entacapone—Nervous system disorder—Methotrexate—urinary bladder cancer	0.000304	0.000509	CcSEcCtD
Entacapone—Thrombocytopenia—Methotrexate—urinary bladder cancer	0.000304	0.000509	CcSEcCtD
Entacapone—Myalgia—Epirubicin—urinary bladder cancer	0.000303	0.000507	CcSEcCtD
Entacapone—Chest pain—Epirubicin—urinary bladder cancer	0.000303	0.000507	CcSEcCtD
Entacapone—Agitation—Doxorubicin—urinary bladder cancer	0.000302	0.000507	CcSEcCtD
Entacapone—Anxiety—Epirubicin—urinary bladder cancer	0.000302	0.000505	CcSEcCtD
Entacapone—Skin disorder—Methotrexate—urinary bladder cancer	0.000301	0.000505	CcSEcCtD
Entacapone—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—urinary bladder cancer	0.000301	0.000504	CcSEcCtD
Entacapone—Hyperhidrosis—Methotrexate—urinary bladder cancer	0.0003	0.000502	CcSEcCtD
Entacapone—Discomfort—Epirubicin—urinary bladder cancer	0.000299	0.000501	CcSEcCtD
Entacapone—Malaise—Doxorubicin—urinary bladder cancer	0.000297	0.000497	CcSEcCtD
Entacapone—Dry mouth—Epirubicin—urinary bladder cancer	0.000296	0.000496	CcSEcCtD
Entacapone—COMT—Metabolism—NQO1—urinary bladder cancer	0.000296	0.000818	CbGpPWpGaD
Entacapone—Vertigo—Doxorubicin—urinary bladder cancer	0.000296	0.000495	CcSEcCtD
Entacapone—Anorexia—Methotrexate—urinary bladder cancer	0.000296	0.000495	CcSEcCtD
Entacapone—Syncope—Doxorubicin—urinary bladder cancer	0.000295	0.000494	CcSEcCtD
Entacapone—Leukopenia—Doxorubicin—urinary bladder cancer	0.000295	0.000493	CcSEcCtD
Entacapone—Confusional state—Epirubicin—urinary bladder cancer	0.000293	0.00049	CcSEcCtD
Entacapone—UGT1A9—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	0.000292	0.000807	CbGpPWpGaD
Entacapone—Palpitations—Doxorubicin—urinary bladder cancer	0.000291	0.000487	CcSEcCtD
Entacapone—Oedema—Epirubicin—urinary bladder cancer	0.00029	0.000486	CcSEcCtD
Entacapone—Hypotension—Methotrexate—urinary bladder cancer	0.00029	0.000485	CcSEcCtD
Entacapone—Loss of consciousness—Doxorubicin—urinary bladder cancer	0.000289	0.000484	CcSEcCtD
Entacapone—COMT—Neuronal System—HRAS—urinary bladder cancer	0.000289	0.000799	CbGpPWpGaD
Entacapone—Cough—Doxorubicin—urinary bladder cancer	0.000287	0.000481	CcSEcCtD
Entacapone—Shock—Epirubicin—urinary bladder cancer	0.000286	0.000478	CcSEcCtD
Entacapone—Convulsion—Doxorubicin—urinary bladder cancer	0.000285	0.000478	CcSEcCtD
Entacapone—Nervous system disorder—Epirubicin—urinary bladder cancer	0.000285	0.000477	CcSEcCtD
Entacapone—Thrombocytopenia—Epirubicin—urinary bladder cancer	0.000284	0.000476	CcSEcCtD
Entacapone—Hypertension—Doxorubicin—urinary bladder cancer	0.000284	0.000476	CcSEcCtD
Entacapone—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	0.000283	0.000473	CcSEcCtD
Entacapone—Skin disorder—Epirubicin—urinary bladder cancer	0.000282	0.000472	CcSEcCtD
Entacapone—Hyperhidrosis—Epirubicin—urinary bladder cancer	0.000281	0.00047	CcSEcCtD
Entacapone—Insomnia—Methotrexate—urinary bladder cancer	0.000281	0.00047	CcSEcCtD
Entacapone—Chest pain—Doxorubicin—urinary bladder cancer	0.00028	0.000469	CcSEcCtD
Entacapone—Myalgia—Doxorubicin—urinary bladder cancer	0.00028	0.000469	CcSEcCtD
Entacapone—Anxiety—Doxorubicin—urinary bladder cancer	0.000279	0.000468	CcSEcCtD
Entacapone—Paraesthesia—Methotrexate—urinary bladder cancer	0.000279	0.000466	CcSEcCtD
Entacapone—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—urinary bladder cancer	0.000278	0.000466	CcSEcCtD
Entacapone—Discomfort—Doxorubicin—urinary bladder cancer	0.000277	0.000464	CcSEcCtD
Entacapone—Anorexia—Epirubicin—urinary bladder cancer	0.000277	0.000463	CcSEcCtD
Entacapone—Dyspnoea—Methotrexate—urinary bladder cancer	0.000277	0.000463	CcSEcCtD
Entacapone—Somnolence—Methotrexate—urinary bladder cancer	0.000276	0.000462	CcSEcCtD
Entacapone—UGT1A9—Metabolism—NAT2—urinary bladder cancer	0.000275	0.00076	CbGpPWpGaD
Entacapone—Dry mouth—Doxorubicin—urinary bladder cancer	0.000274	0.000459	CcSEcCtD
Entacapone—Dyspepsia—Methotrexate—urinary bladder cancer	0.000273	0.000457	CcSEcCtD
Entacapone—Hypotension—Epirubicin—urinary bladder cancer	0.000271	0.000454	CcSEcCtD
Entacapone—Confusional state—Doxorubicin—urinary bladder cancer	0.000271	0.000454	CcSEcCtD
Entacapone—Decreased appetite—Methotrexate—urinary bladder cancer	0.00027	0.000452	CcSEcCtD
Entacapone—Oedema—Doxorubicin—urinary bladder cancer	0.000269	0.00045	CcSEcCtD
Entacapone—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	0.000268	0.000449	CcSEcCtD
Entacapone—Fatigue—Methotrexate—urinary bladder cancer	0.000267	0.000448	CcSEcCtD
Entacapone—Pain—Methotrexate—urinary bladder cancer	0.000265	0.000444	CcSEcCtD
Entacapone—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	0.000264	0.000443	CcSEcCtD
Entacapone—Shock—Doxorubicin—urinary bladder cancer	0.000264	0.000443	CcSEcCtD
Entacapone—Nervous system disorder—Doxorubicin—urinary bladder cancer	0.000263	0.000441	CcSEcCtD
Entacapone—Thrombocytopenia—Doxorubicin—urinary bladder cancer	0.000263	0.00044	CcSEcCtD
Entacapone—Insomnia—Epirubicin—urinary bladder cancer	0.000263	0.00044	CcSEcCtD
Entacapone—Skin disorder—Doxorubicin—urinary bladder cancer	0.000261	0.000437	CcSEcCtD
Entacapone—Paraesthesia—Epirubicin—urinary bladder cancer	0.000261	0.000437	CcSEcCtD
Entacapone—Hyperhidrosis—Doxorubicin—urinary bladder cancer	0.00026	0.000435	CcSEcCtD
Entacapone—Dyspnoea—Epirubicin—urinary bladder cancer	0.000259	0.000433	CcSEcCtD
Entacapone—Somnolence—Epirubicin—urinary bladder cancer	0.000258	0.000432	CcSEcCtD
Entacapone—Anorexia—Doxorubicin—urinary bladder cancer	0.000256	0.000429	CcSEcCtD
Entacapone—Feeling abnormal—Methotrexate—urinary bladder cancer	0.000256	0.000428	CcSEcCtD
Entacapone—Dyspepsia—Epirubicin—urinary bladder cancer	0.000256	0.000428	CcSEcCtD
Entacapone—Gastrointestinal pain—Methotrexate—urinary bladder cancer	0.000254	0.000425	CcSEcCtD
Entacapone—Decreased appetite—Epirubicin—urinary bladder cancer	0.000252	0.000423	CcSEcCtD
Entacapone—Hypotension—Doxorubicin—urinary bladder cancer	0.000251	0.00042	CcSEcCtD
Entacapone—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	0.000251	0.00042	CcSEcCtD
Entacapone—Fatigue—Epirubicin—urinary bladder cancer	0.00025	0.000419	CcSEcCtD
Entacapone—Pain—Epirubicin—urinary bladder cancer	0.000248	0.000416	CcSEcCtD
Entacapone—Constipation—Epirubicin—urinary bladder cancer	0.000248	0.000416	CcSEcCtD
Entacapone—COMT—Metabolism—GSTP1—urinary bladder cancer	0.000247	0.000682	CbGpPWpGaD
Entacapone—Urticaria—Methotrexate—urinary bladder cancer	0.000246	0.000413	CcSEcCtD
Entacapone—Abdominal pain—Methotrexate—urinary bladder cancer	0.000245	0.000411	CcSEcCtD
Entacapone—Body temperature increased—Methotrexate—urinary bladder cancer	0.000245	0.000411	CcSEcCtD
Entacapone—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	0.000245	0.00041	CcSEcCtD
Entacapone—Insomnia—Doxorubicin—urinary bladder cancer	0.000243	0.000407	CcSEcCtD
Entacapone—Paraesthesia—Doxorubicin—urinary bladder cancer	0.000241	0.000404	CcSEcCtD
Entacapone—Dyspnoea—Doxorubicin—urinary bladder cancer	0.000239	0.000401	CcSEcCtD
Entacapone—Feeling abnormal—Epirubicin—urinary bladder cancer	0.000239	0.000401	CcSEcCtD
Entacapone—Somnolence—Doxorubicin—urinary bladder cancer	0.000239	0.0004	CcSEcCtD
Entacapone—UGT1A9—Metabolism—RRM2—urinary bladder cancer	0.000238	0.000656	CbGpPWpGaD
Entacapone—Gastrointestinal pain—Epirubicin—urinary bladder cancer	0.000237	0.000398	CcSEcCtD
Entacapone—Dyspepsia—Doxorubicin—urinary bladder cancer	0.000236	0.000396	CcSEcCtD
Entacapone—Decreased appetite—Doxorubicin—urinary bladder cancer	0.000233	0.000391	CcSEcCtD
Entacapone—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	0.000232	0.000388	CcSEcCtD
Entacapone—Fatigue—Doxorubicin—urinary bladder cancer	0.000232	0.000388	CcSEcCtD
Entacapone—Urticaria—Epirubicin—urinary bladder cancer	0.000231	0.000386	CcSEcCtD
Entacapone—Pain—Doxorubicin—urinary bladder cancer	0.00023	0.000385	CcSEcCtD
Entacapone—Constipation—Doxorubicin—urinary bladder cancer	0.00023	0.000385	CcSEcCtD
Entacapone—COMT—Metabolism—TYMS—urinary bladder cancer	0.00023	0.000634	CbGpPWpGaD
Entacapone—Abdominal pain—Epirubicin—urinary bladder cancer	0.000229	0.000384	CcSEcCtD
Entacapone—Body temperature increased—Epirubicin—urinary bladder cancer	0.000229	0.000384	CcSEcCtD
Entacapone—Hypersensitivity—Methotrexate—urinary bladder cancer	0.000229	0.000383	CcSEcCtD
Entacapone—COMT—Metabolism—NCOR1—urinary bladder cancer	0.000227	0.000627	CbGpPWpGaD
Entacapone—COMT—Metabolism—GSTM1—urinary bladder cancer	0.000227	0.000627	CbGpPWpGaD
Entacapone—Asthenia—Methotrexate—urinary bladder cancer	0.000223	0.000373	CcSEcCtD
Entacapone—Feeling abnormal—Doxorubicin—urinary bladder cancer	0.000221	0.000371	CcSEcCtD
Entacapone—UGT1A9—Metabolism—HPGDS—urinary bladder cancer	0.00022	0.000608	CbGpPWpGaD
Entacapone—UGT1A9—Metabolism—ENO2—urinary bladder cancer	0.00022	0.000608	CbGpPWpGaD
Entacapone—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	0.00022	0.000368	CcSEcCtD
Entacapone—Pruritus—Methotrexate—urinary bladder cancer	0.000219	0.000368	CcSEcCtD
Entacapone—UGT1A9—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	0.000219	0.000604	CbGpPWpGaD
Entacapone—COMT—Metabolism—GPX1—urinary bladder cancer	0.000217	0.0006	CbGpPWpGaD
Entacapone—Hypersensitivity—Epirubicin—urinary bladder cancer	0.000214	0.000358	CcSEcCtD
Entacapone—UGT1A9—Metabolism—GSTT1—urinary bladder cancer	0.000213	0.000589	CbGpPWpGaD
Entacapone—Urticaria—Doxorubicin—urinary bladder cancer	0.000213	0.000357	CcSEcCtD
Entacapone—COMT—Metabolism—ERCC2—urinary bladder cancer	0.000213	0.000589	CbGpPWpGaD
Entacapone—Abdominal pain—Doxorubicin—urinary bladder cancer	0.000212	0.000356	CcSEcCtD
Entacapone—Body temperature increased—Doxorubicin—urinary bladder cancer	0.000212	0.000356	CcSEcCtD
Entacapone—Diarrhoea—Methotrexate—urinary bladder cancer	0.000212	0.000355	CcSEcCtD
Entacapone—UGT1A9—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	0.00021	0.00058	CbGpPWpGaD
Entacapone—Asthenia—Epirubicin—urinary bladder cancer	0.000208	0.000349	CcSEcCtD
Entacapone—Pruritus—Epirubicin—urinary bladder cancer	0.000205	0.000344	CcSEcCtD
Entacapone—Dizziness—Methotrexate—urinary bladder cancer	0.000205	0.000344	CcSEcCtD
Entacapone—COMT—Metabolism—MTHFR—urinary bladder cancer	0.000201	0.000554	CbGpPWpGaD
Entacapone—Diarrhoea—Epirubicin—urinary bladder cancer	0.000199	0.000333	CcSEcCtD
Entacapone—Hypersensitivity—Doxorubicin—urinary bladder cancer	0.000198	0.000331	CcSEcCtD
Entacapone—Vomiting—Methotrexate—urinary bladder cancer	0.000197	0.00033	CcSEcCtD
Entacapone—Rash—Methotrexate—urinary bladder cancer	0.000196	0.000328	CcSEcCtD
Entacapone—Dermatitis—Methotrexate—urinary bladder cancer	0.000195	0.000327	CcSEcCtD
Entacapone—Headache—Methotrexate—urinary bladder cancer	0.000194	0.000325	CcSEcCtD
Entacapone—Asthenia—Doxorubicin—urinary bladder cancer	0.000193	0.000323	CcSEcCtD
Entacapone—Dizziness—Epirubicin—urinary bladder cancer	0.000192	0.000321	CcSEcCtD
Entacapone—Pruritus—Doxorubicin—urinary bladder cancer	0.00019	0.000318	CcSEcCtD
Entacapone—Vomiting—Epirubicin—urinary bladder cancer	0.000185	0.000309	CcSEcCtD
Entacapone—Nausea—Methotrexate—urinary bladder cancer	0.000184	0.000309	CcSEcCtD
Entacapone—Diarrhoea—Doxorubicin—urinary bladder cancer	0.000184	0.000308	CcSEcCtD
Entacapone—Rash—Epirubicin—urinary bladder cancer	0.000183	0.000307	CcSEcCtD
Entacapone—Dermatitis—Epirubicin—urinary bladder cancer	0.000183	0.000306	CcSEcCtD
Entacapone—Headache—Epirubicin—urinary bladder cancer	0.000182	0.000305	CcSEcCtD
Entacapone—Dizziness—Doxorubicin—urinary bladder cancer	0.000178	0.000297	CcSEcCtD
Entacapone—UGT1A9—Metabolism—NQO1—urinary bladder cancer	0.000177	0.00049	CbGpPWpGaD
Entacapone—Nausea—Epirubicin—urinary bladder cancer	0.000172	0.000289	CcSEcCtD
Entacapone—UGT1A9—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	0.000172	0.000475	CbGpPWpGaD
Entacapone—Vomiting—Doxorubicin—urinary bladder cancer	0.000171	0.000286	CcSEcCtD
Entacapone—Rash—Doxorubicin—urinary bladder cancer	0.000169	0.000284	CcSEcCtD
Entacapone—Dermatitis—Doxorubicin—urinary bladder cancer	0.000169	0.000283	CcSEcCtD
Entacapone—Headache—Doxorubicin—urinary bladder cancer	0.000168	0.000282	CcSEcCtD
Entacapone—COMT—Metabolism—PPARG—urinary bladder cancer	0.000163	0.000449	CbGpPWpGaD
Entacapone—Nausea—Doxorubicin—urinary bladder cancer	0.00016	0.000267	CcSEcCtD
Entacapone—COMT—Metabolism—CREBBP—urinary bladder cancer	0.000156	0.000431	CbGpPWpGaD
Entacapone—UGT1A9—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	0.00015	0.000414	CbGpPWpGaD
Entacapone—UGT1A9—Metabolism—GSTP1—urinary bladder cancer	0.000148	0.000409	CbGpPWpGaD
Entacapone—UGT1A9—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	0.000143	0.000395	CbGpPWpGaD
Entacapone—UGT1A9—Metabolism—TYMS—urinary bladder cancer	0.000138	0.00038	CbGpPWpGaD
Entacapone—UGT1A9—Metabolism—NCOR1—urinary bladder cancer	0.000136	0.000375	CbGpPWpGaD
Entacapone—UGT1A9—Metabolism—GSTM1—urinary bladder cancer	0.000136	0.000375	CbGpPWpGaD
Entacapone—UGT1A9—Metabolism—GPX1—urinary bladder cancer	0.00013	0.00036	CbGpPWpGaD
Entacapone—COMT—Metabolism—PTGS2—urinary bladder cancer	0.000128	0.000353	CbGpPWpGaD
Entacapone—UGT1A9—Metabolism—ERCC2—urinary bladder cancer	0.000128	0.000353	CbGpPWpGaD
Entacapone—UGT1A9—Metabolism—MTHFR—urinary bladder cancer	0.00012	0.000332	CbGpPWpGaD
Entacapone—COMT—Metabolism—PTEN—urinary bladder cancer	0.000112	0.000308	CbGpPWpGaD
Entacapone—COMT—Metabolism—EP300—urinary bladder cancer	0.000106	0.000294	CbGpPWpGaD
Entacapone—UGT1A9—Metabolism—PPARG—urinary bladder cancer	9.74e-05	0.000269	CbGpPWpGaD
Entacapone—UGT1A9—Metabolism—CREBBP—urinary bladder cancer	9.36e-05	0.000258	CbGpPWpGaD
Entacapone—UGT1A9—Metabolism—PTGS2—urinary bladder cancer	7.66e-05	0.000212	CbGpPWpGaD
Entacapone—UGT1A9—Metabolism—PTEN—urinary bladder cancer	6.68e-05	0.000185	CbGpPWpGaD
Entacapone—UGT1A9—Metabolism—EP300—urinary bladder cancer	6.37e-05	0.000176	CbGpPWpGaD
